Mibefradil, a T-type Ca2+ channel blocker, protects against mesenteric ischemia-reperfusion-induced oxidative injury and histologic alterations in intestinal mucosa in rats

Basit Öğe Kaydı
dc.contributor.authorOzturk, Hayrettin
dc.contributor.authorOzturk, Hulya
dc.contributor.authorDuran, Hatun
dc.contributor.authorUzunlar, Ali Kemal
dc.date.accessioned2024-04-24T16:02:07Z
dc.date.available2024-04-24T16:02:07Z
dc.date.issued2006
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe purpose of the present study was to investigate whether mibefradil can reduce oxidative stress and histologic damage in the rat small bowel subjected to mesenteric ischemia and reperfusion injury. Thirty Sprague-Dawley rats weighing between 210 and 220 g were divided into three groups, each containing 10 rats: group 1, sham operation; group 2, untreated ischemia-reperfusion; and group 3, ischemia-reperfusion plus mibefradil treatment group. Intestinal ischemia for 45 min and reperfusion for 60 min were applied. Ileal specimens were obtained to determine the tissue levels of MDA, CAT, SOD, and GSH-Px and histologic changes. In group 2, MDA values were significantly increased compared to those in groups 1 and 3. In addition, SOD, CAT, and GSH-Px values decreased significantly in group 2 compared to groups 1 and 3. The intestinal injury score increased significantly in group 2 and 3 rats compared to group 1 rats. However, this increase was reduced in group 3 rats compared to group 2. Histopathologically, the rats in group 1 had essentially normal testicular architecture. In group 2 rats, the lesions varied between grade 3 and grade 5. In contrast, most of the specimens in the mibefradil-treated group 3 showed grade 1 injury. Mibefradil plays a role in attenuating reperfusion injury of the small intestine by depressing free radical production and mucosal injury score and regulating postischemic intestinal perfusion while restoring intestinal microcirculatory blood flow and encountered histologic injury.en_US
dc.identifier.doi10.1007/s10620-005-9060-6
dc.identifier.endpage1460en_US
dc.identifier.issn0163-2116
dc.identifier.issn1573-2568
dc.identifier.issue8en_US
dc.identifier.pmid16868826en_US
dc.identifier.scopus2-s2.0-33748132293en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1454en_US
dc.identifier.urihttps://doi.org/10.1007/s10620-005-9060-6
dc.identifier.urihttps://hdl.handle.net/11468/14641
dc.identifier.volume51en_US
dc.identifier.wosWOS:000240073300024
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofDigestive Diseases and Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIntestinal Ischemia-Reperfusion Injuryen_US
dc.subjectMibefradilen_US
dc.subjectLipid Peroxidationen_US
dc.titleMibefradil, a T-type Ca2+ channel blocker, protects against mesenteric ischemia-reperfusion-induced oxidative injury and histologic alterations in intestinal mucosa in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu